Triple Negative Breast Cancer

Triple Negative Breast Cancer

Breast cancer is a heterogeneous disease comprised of several molecular subtypes that differ

in their biology, behavior and response to treatment. One particularly difficult to treat form is

Triple Negative Breast Cancer (TNBC), so named because tumor cells lack expression of

estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor

receptor 2 (HER2). Specifically testing negative for these three biomarkers places TNBC in

its own unique class comprising approximately 10-20% of all breast cancers.

While affecting a minority of patients, TNBC confers a poorer prognosis relative to other

subtypes due to its propensity for early recurrence, metastasis and limited targeted therapies.

immunotherapeutic approaches optimized for TNBC biology.

Higher rates of pathologic complete response (pCR) seen with neoadjuvant chemotherapy in

TNBC suggest enhanced sensitivity to anthracycline/taxane-based regimens relative to

hormone receptor positive subtypes. However, residual invasive disease after neoadjuvant

treatment still portends a poorer prognosis versus other subtypes achieving minimal residual

disease. Long term follow up from clinical trials revealed approximately 30% of early stage

patients ultimately experiencing disease recurrence within 5 years after upfront surgery alone

despite adjuvant chemotherapy, driving the search for improved adjuvant strategies.

Given its aggressive clinical course and lack of targeted agents, multiple molecular profiling

studies characterized the genomic landscape of TNBC tumors in attempts to uncover new

variation in prognosis.

The BL1 intrinsic subtype, representing approximately 75% of TNBC, features the strongest

immune infiltration and highest mutation burden correlating with improved response to

immune checkpoint inhibitors. However, heterogeneity within TNBC molecular subtypes

remains a challenge impeding targeted therapeutic advances. Neoantigen load from high

mutational burden may support checkpoint blockade efficacy in certain TNBC subgroups

moreso than others based on preliminary data from clinical trials. Continued exploration aims

to refine predictive markers selecting ideal candidates for immunotherapy either as single

agents or in rational combinations with chemotherapy, PARP inhibitors or other targeted

regimens.

disease-free survival compared to standard treatment alone.

Ongoing efforts work towards expanding PARP inhibitor benefit to sporadic (non-hereditary)

forms of BRCA-deficient TNBC through homologous recombination deficiency (HRD)

scoring to predict response. Combination strategies involving PARP inhibition with

immunotherapy also emerge as rational clinical approaches leveraging deficiencies in distinct

pathways to heighten anti-tumor immunity. Ultimately, precision medicine tailoring regimens

according to molecular subgroups may optimize TNBC treatment outcomes relative to

conventional one-size-fits all regimens.

The BL2 intrinsic subtype characterized by low mutation burden responds more optimally to

taxane-containing regimens historically. Anthracycline-based neoadjuvant chemotherapy

Altering treatment regimens according to mutational profiles offers promise towards

improving outcomes beyond traditional regimens alone, though challenges remain in

translating molecular subtyping efforts to routine clinical practice.

Additional targeted agents in various stages of clinical development for certain TNBC

subgroups include histone deacetylase inhibitors, PARP inhibitors for PBRM1-altered

tumors, Bcl-2 inhibitors, Notch inhibitors and androgen receptor axis modulators for LAR

TNBC. Their integration with immunotherapy also increases expected efficacy given immune

stimulation by epigenetic modifiers. Complementary biomarker assays guide enrollment

enriching trials with optimal candidates most likely to benefit versus unselected populations

diluted by unresponsive subgroups. Prospectively validating predictive markers in well

antiandrogen bicalutamide in metastatic LAR disease, prompting further evaluation in the

adjuvant setting through biomarker selected trials.

Combining immunotherapy with chemotherapy addresses the challenge of primary resistance

of atezolizumab added to nab-paclitaxel for first line metastatic TNBC. Whether long term

disease control proves durable or translating similar benefit to early stage adjuvant setting

remains to be seen.

Rare long term survivors from completed trials experience durable responses, suggesting

immunotherapy may potentially cure a minority of selected TNBC cases. Multiple ongoing

early phase trials explore optimizing combination immunotherapy regimens tailored by

and early stage disease in order to heighten and prolong anti-tumor immune stimulation.

validation due safety concerns and limited targeting antigens. Additional studies also explore

Ultimately, continued research integrating multiomics profiling, computational modeling and

clinically annotated biobanks aims to continuously refine TNBC’s heterogeneous landscape

and expose new vulnerabilities for intervention through rational combination therapies

maximizing targeted and immune mediated anti-tumor activity with acceptable toxicity.

While progress remains ongoing, considerable headway characterizing molecular diversity

within this subtype elucidates avenues guiding increasingly personalized treatment

algorithms, supporting improved survivorship compared to traditional anthracycline/taxane

regimens alone through precision oncology frameworks for the future.

Beyond standard chemotherapy, novel targeted agents under study aim to exploit actionable

mutations activating the NF-κB signaling pathway sensitive to targeted MEK inhibition in

PI3K pathway activation represents another vulnerability amenable to targeted strategies.

Several early phase clinical trials are investigating PI3K, mTOR, Akt and dual PI3K/mTOR

The Notch signaling pathway involved in mammary epithelial development also shows

Clinical trials currently evaluate gamma secretase inhibitors such as crenigacestat alone or

combined with cytotoxic regimens in advanced TNBC selected for Notch pathway activation

regardless of mutational status. Optimizing proper predictive biomarkers from genomic and

proteomic profiling represents another area requiring further study to guide Notch targeted

therapy applications.

Dysregulated cell cycle machinery driving unrestrained proliferation represents an Achilles

blocked TNBC growth in preclinical models and achieved encouraging phase II results in

combination with cytotoxic regimens for advanced disease. Larger randomized trials explore

emerges as another potential target given recurrent somatic alterations in approximately 20%

optimism that proper patient selection according to EZH2 status may unveil improved

outcomes. Validation prospective trials comparing matched vs. unmatched cohorts aim to

establish predictive biomarkers guiding optimal implementation in defined molecular

contexts.

Although representing minority subgroups, molecular alterations like fusions involving

FGFR1/2 mutations, NTRK translocations and RB1 inactivation all intersect with targeted

agents under early phase evaluation for selected advanced TNBC harboring driver

dependencies. Leveraging basket trials without histology restrictions enables collecting

meaningful correlative data to assess predictive biomarkers across tumor types sharing

common genomic features. Ultimately, clinically validating molecular subtyping may support

and investigative clinical research opportunities.

Trials evaluate pembrolizumab alone or with chemotherapy based on heightened mutational

neoantigen load association with improved response in the “immune hot” BL1 and IM

intrinsic subtypes.

represent additional strategies leveraging innate immunity against TNBC.

TNBC heterogeneity requires precision therapy approaches pairing effective agents according

to distinct tumor vulnerabilities and immune microenvironment. Potential strategies link

targeted inhibitors impairing DNA repair such as PARP or EZH2 inhibition to

immunotherapy stimulating adaptive immune response and neoantigen recognition. Platinum

agents also operate through DNA damage sensitizing tumors to immune effectors after

initiating immunogenic cell death programs. Basket trials explore synergistic combinations in

molecularly defined subsets based on preclinical rationales involving synthetic lethal

Numerous combination trials evaluate immunotherapy pairing with CDK4/6, PI3K/mTOR,

frameworks correlating genomic signatures to matched treatment response data. This

supports developing clinically actionable biomarkers to guide optimizing standard therapy for

individual patients lacking targetable genomic alterations.

In parallel, leveraging computational biology to model tumor-immune interactions and

synthesize multi-omics datasets may reveal novel targetable immune evasion mechanisms,

signaling dependencies or biomarkers of sensitivity/resistance within molecularly defined

subsets. Identifying “Achilles heels” amenable to intervention or synthetic lethal

vulnerabilities with established agents represents a promising path forward. Consolidating

successes through precision medicine clinical trials networks accelerates progress towards

personalized TNBC care.

While continued improvements impacting survival emerge through targeted therapeutic and

critical towards overcoming limitations of single agent therapies. Sustained funding also

enables clinically annotating diverse TNBC populations to derive externally validated

molecular taxonomies guiding next generation precision trials globally. Ultimately,

estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor

its own unique class comprising approximately 10-20% of all breast cancers.

While affecting a minority of patients, TNBC confers a poorer prognosis relative to other

subtypes due to its propensity for early recurrence, metastasis and limited targeted therapies.

A younger average age of onset around 50 also distinguishes it from other breast cancers

which more commonly develop in older postmenopausal women. Aggressive tumor biology

drives its tendency towards high histologic grades and advanced stages at diagnosis on

directed agents, restricting systemic options mainly to cytotoxic chemotherapy. Ongoing

research aims to alter this treatment paradigm by identifying new molecular targets and

hormone receptor positive subtypes. However, residual invasive disease after neoadjuvant

patients ultimately experiencing disease recurrence within 5 years after upfront surgery alone

despite adjuvant chemotherapy, driving the search for improved adjuvant strategies.

Given its aggressive clinical course and lack of targeted agents, multiple molecular profiling

studies characterized the genomic landscape of TNBC tumors in attempts to uncover new

therapeutic targets. Frequent somatic mutations involve tumor suppressor genes BRCA1/2,

TP53 and cell cycle/DNA repair pathways. Aberrant expression of growth factor receptors

EGFR, c-KIT and IGF1R also emerge as potential targets requiring validation. Distinct

TNBC subtypes have since been proposed by gene expression profiling associating different

mutational frequencies with Luminal Androgen Receptor (LAR), Mesenchymal (M), Basal-

like Immune-activated (IM) and Basal-like (BL1 and BL2) intrinsic subtypes exhibiting

remains a challenge impeding targeted therapeutic advances. Neoantigen load from high

mutational burden may support checkpoint blockade efficacy in certain TNBC subgroups

moreso than others based on preliminary data from clinical trials. Continued exploration aims

like platinum salts and PARP inhibitors based on synthetic lethality when both BRCA

polymerase (PARP) inhibitors such as olaparib and talazoparib as standard adjuvant

treatment options for germline BRCA1/2-mutated early TNBC based on improved invasive

disease-free survival compared to standard treatment alone.

Ongoing efforts work towards expanding PARP inhibitor benefit to sporadic (non-hereditary)

forms of BRCA-deficient TNBC through homologous recombination deficiency (HRD)

scoring to predict response. Combination strategies involving PARP inhibition with

pathways to heighten anti-tumor immunity. Ultimately, precision medicine tailoring regimens

according to molecular subgroups may optimize TNBC treatment outcomes relative to

confers higher pCR rates in non-BL2 subtypes suggesting alternate mechanisms of

impact prognosis.

A substantial minority of TNBC patients also harbor activating PIK3CA mutations

potentially sensitizing tumors to PI3K pathway inhibitors under evaluation in clinical trials.

Altering treatment regimens according to mutational profiles offers promise towards

improving outcomes beyond traditional regimens alone, though challenges remain in

translating molecular subtyping efforts to routine clinical practice.

Additional targeted agents in various stages of clinical development for certain TNBC

subgroups include histone deacetylase inhibitors, PARP inhibitors for PBRM1-altered

tumors, Bcl-2 inhibitors, Notch inhibitors and androgen receptor axis modulators for LAR

stimulation by epigenetic modifiers. Complementary biomarker assays guide enrollment

The luminal androgen receptor (LAR) subtype characterized by androgen signaling

dependence creates opportunities targeting this vulnerability. Phase II trials showed clinical

checkpoint inhibitors achieve objective response rates around 10-15% in unselected

subtypes as expected due to enriched immune contexture.

Combining immunotherapy with chemotherapy addresses the challenge of primary resistance

and exhaustion of preexisting tumor-specific T cells. Phase III studies established the benefit

of atezolizumab added to nab-paclitaxel for first line metastatic TNBC. Whether long term

disease control proves durable or translating similar benefit to early stage adjuvant setting

remains to be seen.

Rare long term survivors from completed trials experience durable responses, suggesting

immunotherapy may potentially cure a minority of selected TNBC cases. Multiple ongoing

Despite therapeutic advances in the adjuvant and metastatic settings, prognosis remains poor

receptors (CAR-T) show promise based on early phase trials albeit requiring further

validation due safety concerns and limited targeting antigens. Additional studies also explore

allogeneic, off-the-shelf NK cells or macrophages directed against TNBC through various

immunological mechanisms as an alternate cell therapy approach.

Ultimately, continued research integrating multiomics profiling, computational modeling and

clinically annotated biobanks aims to continuously refine TNBC’s heterogeneous landscape

and expose new vulnerabilities for intervention through rational combination therapies

maximizing targeted and immune mediated anti-tumor activity with acceptable toxicity.

While progress remains ongoing, considerable headway characterizing molecular diversity

within this subtype elucidates avenues guiding increasingly personalized treatment

regimens alone through precision oncology frameworks for the future.

mutations activating the NF-κB signaling pathway sensitive to targeted MEK inhibition in

preclinical models, supporting phase Ib/II clinical evaluation of MEK inhibitor selumetinib

with or without chemotherapy. Preliminary results revealed promising activity in MAP3K1-

deregulation remains challenging with numerous aberrations potentially impacting response.

broader testing.

The Notch signaling pathway involved in mammary epithelial development also shows

deregulation in a subset of TNBC where inhibition decreases tumor growth in mouse models.

Clinical trials currently evaluate gamma secretase inhibitors such as crenigacestat alone or

combined with cytotoxic regimens in advanced TNBC selected for Notch pathway activation

regardless of mutational status. Optimizing proper predictive biomarkers from genomic and

therapy applications.

the benefit of adding palbociclib or other newer CDK4/6 inhibitors to standard chemotherapy

The histone methyltransferase EZH2 implicated in epigenetic silencing of tumor suppressors

emerges as another potential target given recurrent somatic alterations in approximately 20%

of TNBC. Early clinical data evaluating EZH2 inhibitor tazemetostat and tashinib alone or

combined with chemotherapy show stable disease indicating modest clinical activity, driving

optimism that proper patient selection according to EZH2 status may unveil improved

outcomes. Validation prospective trials comparing matched vs. unmatched cohorts aim to

establish predictive biomarkers guiding optimal implementation in defined molecular

contexts.

Although representing minority subgroups, molecular alterations like fusions involving

FGFR1/2 mutations, NTRK translocations and RB1 inactivation all intersect with targeted

dependencies. Leveraging basket trials without histology restrictions enables collecting

In parallel, leveraging computational biology to model tumor-immune interactions and

synthesize multi-omics datasets may reveal novel targetable immune evasion mechanisms,

signaling dependencies or biomarkers of sensitivity/resistance within molecularly defined

immune modulatory strategies in a precision context, challenges persist including primary

combination regimens leveraging rational synergistic interactions between pathways remain

critical towards overcoming limitations of single agent therapies. Sustained funding also

enables clinically annotating diverse TNBC populations to derive externally validated

molecular taxonomies guiding next generation precision trials globally. Ultimately,

enhancing survivorship through personalized, biomarker-driven treatment algorithms

represents an achievable long-term goal with sustained multidisciplinary collaboration.